| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Wednesday, September 18, 2024 4:41:36 PM
Ahhhh ... yet more profound bullshit.
There will be no need for any biosimilarity trial. People claiming so either have no idea about where the winds are blowing at the FDA, or they have but have an incentive bullshitting about it.
Let's not bullshit any further. We all know.
Lets take a peek at biosimilarity, especially the go to guy in all matters of biosimilarity, Dr. Niazi
And lets look into FDA and MHRAs guidance on these matters. There will be no f...ing trials on biosimilarity on DCVax-L.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377539
And lets enjoy whats coming
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377539
There will be no need for any biosimilarity trial. People claiming so either have no idea about where the winds are blowing at the FDA, or they have but have an incentive bullshitting about it.
Let's not bullshit any further. We all know.
Lets take a peek at biosimilarity, especially the go to guy in all matters of biosimilarity, Dr. Niazi
$NWBO
— 🇩🇰 The Danish Dude 🇬🇱 (@FlemmingBruce) February 6, 2024
Lets look into FDAs stance on biosimilars. And remember this guys name Sarfaraz Niazi Ph.D., SI, FRSB, FPAMS, FAACC. He is a regular one man army regarding FDAs stance on biosimilarity.
Lets see what he wrote about MHRAs stance first.https://t.co/VepkDZuGUN
And lets look into FDA and MHRAs guidance on these matters. There will be no f...ing trials on biosimilarity on DCVax-L.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377539
And lets enjoy whats coming
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377539
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

